Careers  |  Sign In  |  Register  |   Twitter
Free CME

Oncology 2013
Rapid Response From Chicago

Latest Data on Immuno-Oncology Applications in NSCLC and Other Solid Tumors

Course Chair
Roy Herbst, MD, PhD
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT
Faculty
Harriet Kluger, MD
Harriet Kluger, MD
Associate Professor of Medicine (Medical Oncology)
Associate Director
Hematology/Oncology Fellowship Program
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT

CME Front Matter

Title

Rapid Response from Chicago: Evaluating New Data and Clinical Relevance of PD-L1 Antibodies and the Use of Immune Biomarkers

Sponsorship Statement

This continuing medical education activity is sponsored by

Vindico Medical Education

Support Statement

This activity is supported by an educational grant from

Bristol-Myers Squibb

Target Audience

The intended audience for this activity is hematologists, oncologists, medical oncologists, oncology nurse practitioners, oncology physician assistants, and other healthcare professionals involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

At the conclusion of this video series participants should be able to:

  • Assess and apply key data presented at ASCO on the treatment of patients with NSCLC using immunotherapy.
  • Describe the known biomarkers for the immunologic therapies for NSCLC currently in the final stages of development.
  • Review the evidence about emerging immunologic agents and how these drugs may be best combined with other therapies to produce additive or synergistic therapeutic benefits in NSCLC.

Overview

Advances are being rapidly made in the field of immunotherapy for the treatment of solid tumors. During these video interviews, two leading clinicians will discuss studies recently presented on the use of antibodies to programmed death 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) in the treatment of cancers, including non-small cell lung cancer, melanoma, and renal cell carcinoma. The potential impact of combinations of these therapies will also be evaluated, as well as the potential for immune biomarkers to predict response to these treatments.

Course Chair

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT

Faculty

Harriet Kluger, MD
Associate Professor of Medicine (Medical Oncology)
Associate Director
Hematology/Oncology Fellowship Program
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™  through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

This enduring material is approved for 1 year from the date of original release: June 24, 2013 to June 23, 2014.

How To Participate in this Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, complete the CME posttest, and complete and submit the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Planning Committee and Faculty

Roy S. Herbst, MD, PhD
Harriett Kluger, MD

Reviewer

Ronald A. Codario, MD, FACP, CCMEP

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

  • Planning Committee and Faculty members report the following relationship(s):
    • Roy S. Herbst, MD, PhD
      • Consulting Fees: Boehringer Ingelheim, Celgene, Eli Lilly, Pfizer
      • Scientific Advisory Board: Biothera, Diatech, N-of-One, Quintiles
    • Harriett Kluger, MD
      • No relevant financial relationships to disclose.
  • Reviewer reports the following relationship(s):
    • Ronald A. Codario, MD, FACP, CCMEP
      • No relevant financial relationships to disclose.
  • Vindico Medical Education staff report the following relationship(s):
    • No relevant financial relationships to disclose.
      Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
  • BetterCME Staff:
    • The medical director, Maya Mehta, MD, MBA and production staff of BetterCME have nothing to disclose.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2013 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.